Clarity fuel
In a backside-covering move, the FDA has gone public with the "news" that it has nothing to report - yet - about possible heart risks for users of Nexium/Prilosec. Yes, the FDA caught grief for not …
Continue Reading about Nexium the New Avandia? Enough Already! →
A minor comeback for Novartis' Zelnorm. Avandia gets a reprieve, of sorts...to remain on the market, but undoubtedly with a raft of warnings and cautions. Meanwhile, more encouraging data on Actos, …
Fellow blogger Toby Bloomberg over at Diva Marketing writes a review of two pharma companies who are beginning to explore the blogosphere. GSK's effort is focused on just-released OTC product ALLI; …
Some robust pipelines: Glaxo Oncology, and J&J. Cephalon moving more rapidly on oncology candidate Treanda. Glaxo's cervical cancer vaccine Cervarix looking good. Byetta, a diabetes drug from …
The Boston-based law firm of Rosiglitazone, Metformin & Sitaliptin has taken the unprecedented step of filing a global tort lawsuit on behalf of 6 billion residents of Planet Earth, charging a …
Continue Reading about Global Avandia Lawsuit – “We’re in it to Win it!” says Firm →
In my continuing series on how pharmaceutical companies engage the public with their brand on their website homepages, this week we'll take a look at GlaxoSmithKline's home page, www.gsk.com (last …
Continue Reading about Pharma Web Branding, Part 2 – GlaxoSmithKline →
